Key points:
• Overview of the INAVO120 study and its significance
• The unique patient population targeted in the study
• Key findings, including the impressive improvement in progression-free survival (PFS)
• Side effects and management strategies for patients
• The importance of genetic testing in treatment decisions
In this episode of the Oncology Brothers podcast, we dived into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the findings from the INAVO120 study. Drs. Rohit and Rahul Gosain are joined by Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center.
Dr. Jhaveri provides an in-depth overview of the INAVO120 study design, which focused on a high-risk patient population that progressed on or within 12 months of adjuvant endocrine therapy. The study evaluated the efficacy of the novel PI3K inhibitor Inavolisib in combination with fulvestrant and palbociclib. The results were promising, showing a near doubling of progression-free survival (PFS) from 7.3 months in the control arm to 15 months with the triplet regimen, highlighting the potential of this treatment in a challenging patient group.
We discussed the importance of testing for PIK3CA mutations early in the treatment process, especially for patients with aggressive disease. Dr. Jhaveri emphasized the need for comprehensive genomic testing, including liquid biopsies, to guide treatment decisions effectively.
The conversation also covered the triplet regimen’s side effects, including hyperglycemia, stomatitis, and gastrointestinal issues, and how to manage these toxicities in clinical practice. Dr. Jhaveri reassured us that anabolic steroids' safety profile aligns with what is already known about similar agents, making them a viable option for patients.
Finally, we touch on ongoing studies exploring the combination of Inavolisib with other CDK4-6 inhibitors and the potential for future research to further refine treatment strategies in this rapidly evolving landscape.
Join us as we unpack these critical developments in breast cancer treatment and look forward to seeing you at SABCS 2024!
Listen Podcast on Your Favourite Platform
